The BCG Vaccine is a vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.
For years, scientists have been trying to come up with a better way to protect people against tuberculosis, the disease caused by infection with the Mycobacterium tuberculosis bacteria.
Vaccinations have begun in a Phase 1 human clinical trial testing a freeze-dried, temperature-stable formulation of an experimental tuberculosis vaccine candidate.
GlaxoSmithKline has come up with an experimental vaccine against tuberculosis (TB) that has shown effective prevention of the infection in half of the population it has been administered to. This could be a breakthrough in preventing the killer disease say researchers since most of the recent vaccines developed against the disease have failed to show efficacy.
Aeras, a nonprofit organization dedicated to developing vaccines against tuberculosis (TB), today announced the publication of the full results from a Phase 2, randomized, controlled clinical trial of two TB vaccines-- the currently available BCG vaccine and an investigational vaccine, H4:IC31--in the New England Journal of Medicine (NEJM).
LSTM's Dr Maxine Caws is co-lead investigator on an advanced genetics study published in Nature Genetics(link is external), which has shown that a virulent strain of tuberculosis (TB) has adapted to transmit among young adults in Ho Chi Minh City, Vietnam.
Tuberculosis (TB), an infectious disease which attacks the lungs, claims someone's life every 20 seconds and 1.5 million lives worldwide every year.
Childhood asthma is a serious public health challenge in Québec and throughout the world. Although the immune mechanisms implicated in the development of childhood asthma are not fully understood, some studies seem to suggest that the BCG vaccine, used in tuberculosis prevention, may have a protective effect on childhood asthma.
Previously thought to be effective for 10-15 years, a new case-control study found that if given in early teenage years (12-13), the Bacillus Calmette-Guérin (BCG) vaccine protected over 50% of UK children against TB for at least 20 years, then waned.
Interim results from a FDA-approved clinical trial testing the generic vaccine bacillus Calmette-Guérin (BCG) to reverse advanced type 1 diabetes are being presented at the 75th Scientific Sessions of the American Diabetes Association.
Newborns are highly vulnerable to infections and don't respond optimally to most vaccines because their young immune systems typically mount weak antibody responses.
New research findings provide insight into the immune system pathways that may be key to developing an effective tuberculosis (TB) vaccine.
A study led by investigators from the Ragon Institute of MGH, MIT and Harvard finds evidence that antibody protection may help control infection with the bacteria that causes tuberculosis (TB).
A new skin test for tuberculosis infection has proven safe, easy to administer and accurate in two Phase III clinical trials, according to research presented at the ATS 2016 International Conference.
A team of scientists led by Oxford University have made a discovery that could improve our chances of developing an effective vaccine against Tuberculosis.
When results from a landmark tuberculosis vaccine trial in Cape Town, South Africa were published in The Lancet in February 2013, the headlines were grim, despite hopes that the trial would point toward a successful way to thwart one of the globe's biggest public health threats.
The Global Health Innovative Technology Fund, which in the last two years has invested US$43 million to develop innovative tools for fighting diseases worldwide, today announced it is investing $10.7 million at multiple points in the product development pipeline to seek new interventions for malaria, tuberculosis (TB), leishmaniasis and dengue.
For about the last 25 years, the cardiology group here have been developing a platform technology for both the diagnosis and treatment of atherosclerosis. The group began at Northwestern University, Chicago, under the direction of Dr. David McPherson and he continues to lead the group.
Generex Biotechnology Corporation today announced that it has entered into a non-binding Letter of Intent (LOI) with Hema Diagnostic Systems, LLC (HDS), a Florida company that designs and manufactures proprietary infectious disease detection technologies.
Not only the acquired immune system but also the innate immune system has a memory. And the BCG vaccine against tuberculosis can stimulate this memory. After a BCG vaccination the innate immune system responds better to a wide range of other infections. Mihai Netea and colleagues from Radboud university medical center discovered and described how that works. They think that the old vaccine could be useful for specific target groups, such as the elderly.
A new systematic review of animal studies testing a vaccine for tuberculosis raises questions about whether the studies provided sufficient evidence to move into trials of children.